Phase II evaluation of amonafide in rena
โ
Celestia S. Higano; Phyllis Goodman; John B. Craig; Julie A. Kish; Saul E. Rivki
๐
Article
๐
1991
๐
Springer US
๐
English
โ 205 KB
Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days. There were no responders, 6 patients had stable disease, 14 experienced progressive disease and 4 were assumed to be non-responders as no evaluation wa